It is termed a specific therapy as it precisely targets the CD38 which can be overexpressed about the multiple myeloma cells. Daratumumab is from a class of medicines named CD38 monoclonal antibodies. Daratumumab-mediated favourable oblique antiglobulin check could persist for as many as six months after the final daratumumab infusion https://juliusdnuci.wikibestproducts.com/1483724/5_easy_facts_about_teriparatide_forteo_abaloparatide_tymlos_described